Phenotypes of GCA: Pt dx by PET compared to TA biopsy were: - younger -longer disease before dx -more frequent extremity claudication (still overall low) -less cranial / TA sx @RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db

A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv

Cool study using vasculitis patient-powered reserach network (VPPRN) "SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission Very important impacter of QOL in AAV #ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS

Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower sensitivity (79%) but better specificity (96%) @RheumNow #ACR25 Abstr#750 https://t.co/SIkAkEeYh1

ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl

Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep advocating for trials in all populations! #ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts: - tDR-1 higher = less develop RA - can predict seropos RA development - in vitro type 1 IFN mapping checks out Useful in itself, but importantly: why does it happen? #ACR25 ABST0775 @RheumNow https://t.co/ep99dNAzFV

No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It sure feels like GCA comes in waves, but data does not bear this out #ACR25 @RheumNow Abstr#0754 https://t.co/4y2elYmCRT